TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.